31.08.2005 16:58:00

Lifecore Expands Direct Selling of Dental Implants to France

LIFECORE BIOMEDICAL, INC. (NASDAQ:LCBM) announced todaythat it has acquired its former distributor, Bardo-Biotech SAS, andwill market the Company's oral restorative products directly inFrance. The new subsidiary, Lifecore Biomedical SAS, is based inBeauzelle, France with operations under the direction of Mr. JoelBardeau, General Manager.

"The establishment of a subsidiary in France complements oursubsidiaries in Germany, Italy and Sweden, as we focus our marketingstrategy to position the Lifecore brand in the key European markets,"said Lifecore President and CEO, Dennis J. Allingham. "We believe thatFrance, one of the largest dental implant markets in Europe,represents a growth opportunity best served by the integration ofdirect management as part of our marketing initiative. We are pleasedto add Mr. Bardeau to our management team and are confident that hisexperience will provide the focus to drive continued penetration ofthis major market."

Lifecore Biomedical develops, manufactures, and marketsbiomaterials and medical devices for use in various surgical marketsthrough two divisions, the Hyaluronan Division and the OralRestorative Division. The Hyaluronan Division conducts its businessthrough OEM and contract manufacturing alliances in the ophthalmic,orthopedic, veterinary and gynecologic surgical fields. The OralRestorative Division conducts its dental implant business throughdirect sales and marketing in the United States, France, Germany,Italy, and Sweden, and through 24 distributors in 34 countries, whichinclude Portugal, Spain and the United Kingdom.

Certain statements in this release are forward-looking statementsas defined in the Private Securities Litigation Reform Act of 1995,including references regarding the marketing strategy and branding ofthe products and statements related to the growth of the oralrestorative business. Because of numerous risks and uncertainties inthe complex regulatory and competitive aspects of Lifecore's businessactivity, including continued sales of its oral restorative productsin France and Europe; actual results may differ materially from thoseimplied. Investors are strongly cautioned to review more detaileddiscussions of those risks presented in the Company's filings with theSecurities and Exchange Commission, including Exhibit 99.1 toLifecore's annual report on Form 10-K for the fiscal year ending June30, 2004.

General corporate information is available on the internet atwww.lifecore.com.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Lifecore Biomedical Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Lifecore Biomedical Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 19 391,96 -1,20%